Histone Deacetylase 3 Inhibitors for Treating Demyelinating Diseases
HDAC3 inhibitors enhance myelin repair in white matter injury and demyelinaiting diseases
Treatment with Histone Deacetylase 3 (HDAC3) Inhibitors can promote myelination in the white matter during development. HDAC3 inhibitors can also enhance re-myelination and functional nerve recovery in the central and peripheral nerve systems (CNS and PNS) in animal models of multiple sclerosis. Targeting HDAC3 with these inhibitors also rejuvenates the age-related decline in functional recovery after nerve injury.
- Inhibiting histone deacetylase 3 may be used to treat demyelinating diseases.
- Histone deacetylase 3 inhibitors repair white matter damage and nerve regeneration after injury.
Histone deacetylase 3 inhibitors have been identified for treating demyelinating diseases and diseases with white matter injury.
Most of the nerves in your body are covered with a protective layer called myelin. Demyelinating disorders are any conditions that damage myelin. There are several demyelinating diseases, the most common being Multiple Sclerosis (MS). It is estimated that more than 2.3 million people worldwide are affected by MS.
Qing (Richard) Lu, PhD., Division of Experimental Hematology and Cancer Biology